Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Holdings Boosted by Capital International Investors

Capital International Investors boosted its holdings in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 21.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,895,481 shares of the biopharmaceutical company’s stock after purchasing an additional 520,496 shares during the period. Capital International Investors owned about 6.80% of Ultragenyx Pharmaceutical worth $154,213,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Capital Research Global Investors grew its holdings in shares of Ultragenyx Pharmaceutical by 1.4% during the 2nd quarter. Capital Research Global Investors now owns 5,183,330 shares of the biopharmaceutical company’s stock worth $321,937,000 after acquiring an additional 71,811 shares during the period. BlackRock Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 10.4% during the 2nd quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock worth $217,237,000 after acquiring an additional 330,911 shares during the period. Vanguard Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company’s stock worth $194,421,000 after acquiring an additional 135,335 shares during the period. State Street Corp boosted its position in shares of Ultragenyx Pharmaceutical by 21.4% in the 2nd quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock worth $95,417,000 after purchasing an additional 270,729 shares in the last quarter. Finally, Pictet Asset Management Ltd. boosted its position in shares of Ultragenyx Pharmaceutical by 27.4% in the 3rd quarter. Pictet Asset Management Ltd. now owns 750,407 shares of the biopharmaceutical company’s stock worth $39,967,000 after purchasing an additional 161,196 shares in the last quarter. Institutional investors own 94.10% of the company’s stock.

Several equities analysts recently issued reports on the company. Barclays upped their price objective on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 5th. Canaccord Genuity set a $80.00 price objective on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. BidaskClub lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Finally, Wedbush upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $62.00 price objective for the company in a research report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company. Ultragenyx Pharmaceutical currently has an average rating of “Hold” and a consensus target price of $72.40.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) traded up $2.91 during trading hours on Tuesday, hitting $49.29. 467,804 shares of the stock traded hands, compared to its average volume of 378,400. Ultragenyx Pharmaceutical Inc has a 1-year low of $43.14 and a 1-year high of $91.35. The firm has a market capitalization of $1,980.00, a P/E ratio of -7.07 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.87). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. The company’s quarterly revenue was up 81.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.64) earnings per share. analysts expect that Ultragenyx Pharmaceutical Inc will post -7.29 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.truebluetribune.com/2018/01/03/capital-international-investors-acquires-520496-shares-of-ultragenyx-pharmaceutical-inc-rare.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply